# JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office: T-210J, Shahpur Jat, New Delhi 110049

## Unaudited Financial Results for the Quarter ended 30.09.2012

|           | Unaudited Financia   | Results for the                              | Quarter ended                                | 30.09.2012                                   |  |   |                     |
|-----------|--|--|--|--|--|---|---------------------|
|           | D. C.  |  |  |  |  |   | Rs. in lacs         |
|           | Particulars  | 3 months<br>ended<br>30.09.2012<br>Unaudited | 3 months<br>ended<br>30.06.2012<br>Unaudited | 3 months<br>ended<br>30.09.2011<br>Unaudited | 6 Months<br>ended<br>30.09.2012<br>Unaudited | 6 Months<br>ended<br>30.09.2011<br>Unudited | Ended<br>31.03.2012 |
|           | Income from operations     Net sales/income from Operations (Net of excise duty)                     | 4178.33                                      | 2722.00                                      |  |  | ondanca                                     | Addited             |
|           | b Other Operating Income   | 4170.33                                      | 3722.69                                      | 4765.49                                      | 7901.02                                      | 8845.53                                     | 17651.39            |
|           | Total Income from operations (net)  2 Expenses   | 4178.33                                      | 3722.69                                      | 4765.49                                      | 7901.02                                      | 8845.53                                     | 17651.39            |
|           | z Expenses a Cost of materials consumed  |  |  |  |  |   |                     |
|           | Purchases of stock-in-trade  | 1437.22                                      | 1651.38                                      | 2367.77                                      | 3088.60                                      | 4449.21                                     | 7955.91             |
| (         | c. Changes in inventories of finished goods, work in progress and                                    | 308.25                                       | 454.25                                       | 290.03                                       | 762.50                                       | 436.28                                      | 1572.28             |
| c         | Stock in trade  Employee benefits expenses   | 332.82                                       | -361.54                                      | -368.32                                      | -28.72                                       | -551.53                                     | -1073.60            |
| e         | Depreciation and amortisation expense  | 963.73                                       | 867.06                                       | 927.74                                       | 1830.79                                      | 1778.23                                     | 3650.73             |
| 1         | . Other expenses   | 69.92  | 65.18  | 62.15  | 135.10                                       | 120.08                                      | 253.58              |
|           | Total expenses   | 866.03<br>3977.97                            | 915.52                                       | 1061.50                                      | 1781.55                                      | 1907.20                                     | 3884.60             |
| (         | Profit from Operations before Other Income, Finance Cost and Exceptional items (1-2)                 |  | 3591.85                                      | 4340.87                                      | 7569.82                                      | 8139.47                                     | 16243.50            |
| 4         | Other Income   | 200.36                                       | 130.84                                       | 424.62                                       | 331.20                                       | 706.06                                      | 1407.89             |
| ٤         | Profit from ordinary activities before finance cost and<br>Exceptional items (3+4)                   | 200.36                                       | 130.84                                       | 6.01<br>430.63                               | 0.00<br>331.20                               | 6.01<br>712.07                              | 36.92               |
| ε         | Finance Cost   | 125.40                                       |  |  | 001.20                                       | 7 12.07                                     | 1444.81             |
| 7         |  | 125.42                                       | 115.78                                       | 103.62                                       | 241.20                                       | 179.65                                      | 435.82              |
| 8         | Exceptional Items (5-6) Exceptional Items  | 74.94  | 15.06  | 327.01                                       | 90.00  | 532.42                                      | 1008.99             |
| 9         | Profit(+)/Loss(-) from Ordinary Activities before tax (7+8)  | 74.94  | 15.06  | 327.01                                       | 90.00  | 532.42                                      | 1008.99             |
| 10        | Tax expense  |  |  |  |  |   |                     |
| 11        |  | 33.00<br>41.94                               | 15.00<br>0.06                                | 73.00<br>254.01                              | 48.00<br>42.00                               | 113.00<br>419.42                            | 263.31<br>745.68    |
| 12        | Extraordinary Items (net of tax expense Rs. lacs)  |  |  |  |  |   |                     |
| 13        | Net Profit(+)/Loss(-) for the period(11-12)  | 44.04  |  |  |  |   |                     |
| 14        | Share of profit/(Loss) of associates Minority interest   | 41.94  | 0.06   | 254.01                                       | 42.00  | 419.42                                      | 745.68              |
| 16        | Net Profit/(Loss) after taxes, minority interest and share of profit/(loss) of associates (13-14-15) | 41.94  | 0.06   | 254.01                                       | 42.00  | 419.42                                      | 745.68              |
| 17        | Paid up Eq. Sh. Cap.(Face value Rs. 5)   | 1200.00                                      | 4000 00                                      |  |  |   | 140.00              |
| 18        | Reserves excluding Revaluation reserves as per Balance sheet of pr. Accounting yr                    | 1309.90                                      | 1309.90                                      | 1309.90                                      | 1309.90                                      | 1309.90                                     | 1309.90<br>7208.47  |
| 19.<br>a. | Earnings Per Share (before extraordinary items)  |  |  |  |  |   |                     |
| b.        |  | 0.16   | 0.00   | 0.97   | 0.16   | 1.60  | 2.85                |
|           | Earnings Per Share (after extraordinary items)   | 0.16   | 0.00   | 0.97   | 0.16   | 1.60  | 2.85                |
| a.        | Basic (Rs.)  | 0.16   | 0.00   |  |  |   |                     |
| b.        | Diluted (Rs.)  | 0.16   | 0.00<br>0.00                                 | 0.97<br>0.97                                 | 0.16   | 1.60  | 2.85                |
| Α         | PARTICULARS OF SHAREHOLDING  |  | 0.00   | 0.57   | 0.16   | 1.60  | 2.85                |
| 1         | Public Shareholding  |  |  |  |  |   |                     |
|           | - Number of shares   | 0000000                                      |  |  |  |   |                     |
|           | - Percentage of Shareholding   | 8962360<br>34.21%                            | 8962360                                      | 8962360                                      | 8962360                                      | 8962360                                     | 8962360             |
| 2         | Promoter and promoter group shareholding   | 34.21%                                       | 34.21%                                       | 34.21%                                       | 34.21%                                       | 34.21%                                      | 34.21%              |
| Α         | Pledged / encumbered   |  |  |  |  |   |                     |
| -         | Number of shares   |  |  |  |  |   |                     |
| -         | Percentage of shares (as a % of the total shareholding of  |  |  |  |  |   |                     |
|           | Promoter and promoter group)   |  |  |  |  |   |                     |
| -         | Percentage of shares (as a % of the total share capital of the Company)                              |  |  |  |  |   |                     |
| В         | Non - encumbered   |  |  |  |  |   |                     |
| -         | Number of shares   | 17225640                                     | 47005040                                     |  |  |   |                     |
| -         | Percentage of shares (as a % of the total shareholding of  | 17235640<br>100%                             | 17235640<br>100%                             | 17235640<br>100%                             | 17235640                                     | 17235640                                    | 17235640            |
|           | Promoter and promoter group) Percentage of shares (as a % of the total share capital of the          | 65.79%                                       | 65.79%                                       |  | 100%   | 100%  | 100%                |
|           | Company)   | 23070  | 55.157a                                      | 65.79%                                       | 65.79%                                       | 65.79%                                      | 65.79%              |
| В         | INVESTOR COMPLAINTS  |  |  |  |  |   |                     |
|           | Pending at the beginning of the quarter Received during the quarter                                  | 0  |  |  |  |   |                     |
|           | Disposed of during the quarter   | 27   |  |  |  |   |                     |
|           | Remaining unresolved at the end of the quarter   | 27<br>0                                      |  |  |  |   |                     |
|           |  | U  |  |  |  |   |                     |

- Notes

  1. The Unaudited Financial Results for the Quarter ended 30.9.2012 have been reviewed by the Audit Committee. The Board of Directors has approved the financial Results at its meeting held on 10.11.2012

  2. The Company is operating only in the Pharmaceuticals segment and hence compliance has been made under AS-17.

  3. The net effect of the deferred taxation for the Quarter as per AS-22 has been taken.

  4. Previous year figures have been regrouped / rearranged wherever necessary.

Place : New Delhi Date : 10.11.2012



By Order of the Board

ace-Rajpal Singh Kochhar Chairman & Managing Director

# JAGSONPAL PHARMACEUTICALS LIMITED

Regd. Office: T-210J, Shahpur Jat, New Delhi 110049

# Statement of Assets and Liabilities

| Re la lace  | As at            | 30.09.2011   | 3.00  | 0.00  | 0.00<br>0.00<br>6342.68  | 3067.49<br>3632.48<br>665.66<br>206.74<br>0.00<br>7572.37  | 13915.05                         |
|-------------|------------------|--|---|---|--|--|----------------------------------|
|             | As at            | 30.09.2012   | 3.00  | 0.00  | 0.00   | 3674.67<br>4136.64<br>965.87<br>342.38<br>0.00<br>9119.56  | 15545.96                         |
|             | B ASSETS         | <ul><li>1 Non-current assets</li><li>(a) Fixed Assets</li></ul>                              | (b) Goodwill<br>(c) Non-current investments | <ul><li>(d) Deferred tax assets (net)</li><li>(e) Long term loans and advance</li></ul> | (f) Other non-current assets<br>Sub-total - Non-current assets | 2 Current assets (a) Current investments (b) Inventories (c) Trade receivables (d) Cash and Cash equivalents (e) Short term loans and advance (f) Other current assets Sub-Total - Current assets  | TOTAL - ASSETS                   |
| Rs. In lacs | As at            | 1309.90  | 8400.91<br>9710.81                          | 0.00  | 0.00   | 21.81<br>351.77<br>0.00<br>0.00<br>373.58<br>2347.64<br>567.87<br>436.41<br>478.74<br>3830.66  | 13915.05                         |
|             | As at 30,09,2012 | 1309.90  | 9894.54                                     | 0.00  | 0.00   | 26.92<br>428.27<br>0.00<br>0.00<br>455.19<br>3547.47<br>655.02<br>468.72<br>525.02   | 15545.96                         |
|             |                  | <ol> <li>Shareholders' funds</li> <li>Share Capital</li> <li>Reserves and surplus</li> </ol> | Sub-total - Shareholders' funds             | <ol> <li>Share application money pending allotment</li> </ol>                           | 3 Minority interest  | 4 Non-current liabilities (a) Long term borrowings (b) Deferred tax liabilities (net) (c) Other long term liabilities (d) Long term provisions Sub-total - Non-current liabilities 5 Current liabilities (a) Short term borrowing (b) Trade payables (c) Other current liabilities (d) Short term provisions Sub-Total - Current liabilities | I UI AL - EQUITY AND LIABILITIES |

Place : New Delhi Date : 10.11.2012

Rajpal Singh Kochhar Chairman & Managing Director

For Jagsonpal Pharmaceuticals Limited

# P.P. THUKRAL & CO. CHARTERED ACCOUNTANTS

42, Ground Floor, World Trade Centre, Babar Road, New Delhi - 110 001

Ph. (O): 23413486

E-mail: sureshsethi62@yahoo.com

# Limited review report for Jagsonpal Pharmaceuticals Limited

To whom it may concern

We have reviewed the accompanying statement of unaudited financial results of Jagsonpal Pharmaceuticals Limited for the period ended 30.09.2012, except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/ Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards<sup>1</sup> and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

for P. P. THUKRAL & CO., Chartered Accountants

Place: New Delhi Date: 10.11.2012



8URESH SETHI PARTNER F.R. No. 000632 N Membership no. 89318